{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:38:22Z","timestamp":1791974302605,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["17fk0210304h0003"],"award-info":[{"award-number":["17fk0210304h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12876-018-0900-1","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T03:57:40Z","timestamp":1541476660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan"],"prefix":"10.1186","volume":"18","author":[{"given":"Norio","family":"Akuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuji","family":"Arase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Fujiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Sezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"900_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221\u201331.","journal-title":"N Engl J Med"},{"key":"900_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/hep.21347","volume":"44","author":"R Williams","year":"2006","unstructured":"Williams R. Global changes in liver disease. Hepatology. 2006;44:521\u20136.","journal-title":"Hepatology"},{"key":"900_CR3","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1053\/j.gastro.2008.02.077","volume":"134","author":"DM Torres","year":"2008","unstructured":"Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682\u201398.","journal-title":"Gastroenterology"},{"key":"900_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.22603","volume":"49","author":"R Vuppalanchi","year":"2009","unstructured":"Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49:306\u201317.","journal-title":"Hepatology"},{"key":"900_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ajg.2011.327","volume":"107","author":"Y Kawamura","year":"2012","unstructured":"Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107:253\u201361.","journal-title":"Am J Gastroenterol"},{"key":"900_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","volume":"20","author":"Y Sumida","year":"2014","unstructured":"Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:475\u201385.","journal-title":"World J Gastroenterol"},{"key":"900_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0032-1306421","volume":"32","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. 2012;32:3\u201313.","journal-title":"Semin Liver Dis"},{"key":"900_CR8","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675\u201385.","journal-title":"N Engl J Med"},{"key":"900_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390.","journal-title":"Lancet"},{"key":"900_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hep4.1019","volume":"1","author":"N Akuta","year":"2017","unstructured":"Akuta N, Watanabe C, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, et al. Effects of a sodium - glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017;1:46\u201352.","journal-title":"Hepatol Commun"},{"key":"900_CR11","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/hep.24268","volume":"53","author":"ZM Younossi","year":"2011","unstructured":"Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874\u201382.","journal-title":"Hepatology"},{"key":"900_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389\u201397.","journal-title":"Gastroenterology"},{"key":"900_CR13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"900_CR14","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467\u201374.","journal-title":"Am J Gastroenterol"},{"key":"900_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hep.27173","volume":"60","author":"P Bedossa","year":"2014","unstructured":"Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565\u201375.","journal-title":"Hepatology"},{"key":"900_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265\u201373.","journal-title":"J Hepatol"},{"key":"900_CR17","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.cgh.2017.04.040","volume":"15","author":"K Bj\u00f6rkstr\u00f6m","year":"2017","unstructured":"Bj\u00f6rkstr\u00f6m K, St\u00e5l P, Hultcrantz R, Hagstr\u00f6m H. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2017;15:1461\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"900_CR18","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547\u201354.","journal-title":"Hepatology"},{"key":"900_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1872-034X.2011.00915.x","volume":"42","author":"Y Arase","year":"2012","unstructured":"Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res. 2012;42:264\u201372.","journal-title":"Hepatol Res"},{"key":"900_CR20","doi-asserted-by":"crossref","unstructured":"Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, et al. Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease. Hepatol Res. 2017 Jun 19. [Epub ahead of print].","DOI":"10.1111\/hepr.12925"},{"key":"900_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.maturitas.2008.11.026","volume":"62","author":"U Gaspard","year":"2009","unstructured":"Gaspard U. Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women. Maturitas. 2009;62:362\u20135.","journal-title":"Maturitas"},{"key":"900_CR22","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.dld.2015.08.004","volume":"47","author":"A Lonardo","year":"2015","unstructured":"Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47:997\u20131006.","journal-title":"Dig Liver Dis"},{"key":"900_CR23","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.2174\/1381612811319290003","volume":"19","author":"A Lonardo","year":"2013","unstructured":"Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des. 2013;19:5177\u201392.","journal-title":"Curr Pharm Des"},{"key":"900_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1053\/j.seminoncol.2012.05.002","volume":"39","author":"C Della Corte","year":"2012","unstructured":"Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384\u201398.","journal-title":"Semin Oncol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-018-0900-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-018-0900-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-018-0900-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T19:17:31Z","timestamp":1572981451000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-018-0900-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1186\/s12876-018-0900-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"28 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in compliance with the International Conference on Harmonization guidelines for Good Clinical Practice (E6) and the 2013 Declaration of Helsinki. The protocol was approved by the institutional review board at Toranomon Hospital (number; 953). Written informed consent was provided by all patients prior to liver biopsy.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"(1) Hiromitsu Kumada has received honoraria from MSD K.K., Bristol-Myers Squibb, Gilead Sciences, AbbVie Inc., and Dainippon Sumitomo Pharma. (2) Norio Akuta has received an honorarium from Bristol-Myers Squibb and AbbVie Inc. (3) Yoshiyuki Suzuki has received an honorarium from Bristol-Myers Squibb and AbbVie Inc. All other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"165"}}